XML 99 R85.htm IDEA: XBRL DOCUMENT v3.25.0.1
Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share (Details) - shares
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Antidilutive securities 26,826,977 25,133,607 19,102,419
Employee Stock Option      
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Antidilutive securities 12,744,898 13,839,067 13,892,287
Nonvested Restricted Stock Units Outstanding      
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Antidilutive securities 10,584,853 9,630,579 4,799,850
Nonvested Market-based Restricted Stock Units Outstanding Granted      
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Antidilutive securities 3,497,226 1,663,961 410,282